iTeos Therapeutics (NASDAQ:ITOS) Posts Earnings Results, Beats Expectations By $0.13 EPS

iTeos Therapeutics (NASDAQ:ITOS) announced its quarterly earnings results on Wednesday. The company reported ($1.01) EPS for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.13, Zacks reports.

iTeos Therapeutics Price Performance

NASDAQ:ITOS opened at $7.26 on Thursday. iTeos Therapeutics has a one year low of $6.67 and a one year high of $18.75. The business has a fifty day moving average price of $7.54 and a 200-day moving average price of $9.55. The firm has a market capitalization of $265.24 million, a price-to-earnings ratio of -2.30 and a beta of 1.38.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 target price on shares of iTeos Therapeutics in a research report on Thursday, January 16th. Wedbush reissued an “outperform” rating and issued a $25.00 target price on shares of iTeos Therapeutics in a report on Wednesday. Finally, Wells Fargo & Company cut their price target on iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating for the company in a research note on Thursday, December 19th.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.